JAZZ
HealthcareJazz Pharmaceuticals plc · Biotechnology · $15B
What is Jazz Pharmaceuticals plc?
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing treatments for serious unmet medical needs. Its core therapeutic areas span neuroscience — particularly sleep medicine — and oncology, including blood cancers and solid tumors.
Jazz generates revenue by developing, acquiring, and selling specialty pharmaceutical products across the United States, Europe, and international markets. Its neuroscience franchise centers on treatments for narcolepsy and related sleep disorders, while its oncology portfolio addresses rare and aggressive cancers. The company pursues both marketed products and a pipeline of clinical-stage candidates, aiming to expand its reach in conditions where treatment options remain limited.
Jazz Pharmaceuticals was founded in 2007 and is headquartered in Dublin, Ireland.
- Xywav and Xyrem — oxybate therapies for narcolepsy and idiopathic hypersomnia
- Sunosi — treatment for excessive daytime sleepiness
- Vyxeos — therapy for adults with acute myeloid leukemia
- Zepzelca — treatment for metastatic small cell lung cancer
- JZP458 and JZP385 — pipeline candidates in oncology and movement disorders
Is JAZZ a Good Stock to Buy?
UQS Score rates JAZZ as Below Average overall, reflecting meaningful challenges across several key quality dimensions.
The Valuation pillar stands out as Attractive, suggesting the market may already be pricing in a significant portion of the company's headwinds — which can be relevant context for investors weighing risk against entry price. The Moat pillar registers as Neutral, reflecting some degree of product differentiation in specialty therapeutic niches.
The Quality, Growth, and Risk pillars all register as Weak, pointing to concerns around financial durability, near-term growth visibility, and the broader risk profile facing the business.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does JAZZ pay dividends?
No — Jazz Pharmaceuticals plc does not currently pay a dividend.
Jazz Pharmaceuticals does not currently pay a dividend. This is common among specialty biopharmaceutical companies that prioritize capital allocation toward pipeline development, acquisitions, and debt management. Investors seeking income from this position would need to look elsewhere, as Jazz's capital strategy centers on reinvestment rather than shareholder distributions.
When does JAZZ report earnings?
Jazz Pharmaceuticals reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's recent results have reflected the pressures visible in its UQS pillar profile — particularly around growth and financial quality. Investors should monitor how the neuroscience franchise and oncology pipeline contribute to revenue trends over coming quarters.
For the most recent quarter's results and guidance, visit Jazz Pharmaceuticals' official investor relations page.
JAZZ Price History
+11.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Jazz Pharmaceuticals plc?
Based on Jazz Pharmaceuticals plc's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
JAZZ Long-term Outlook
The fundamental outlook for Jazz is shaped by a Weak Growth pillar and Weak Risk pillar, suggesting limited near-term revenue acceleration and an elevated uncertainty profile. The Attractive Valuation pillar indicates the stock may reflect these challenges in its current pricing. Longer-term trajectory will depend heavily on pipeline execution — particularly in narcolepsy and oncology — and the company's ability to manage its debt load while advancing clinical candidates.
Growth drivers
- Expansion of the oxybate franchise into idiopathic hypersomnia and broader narcolepsy populations
- Advancement of oncology pipeline candidates, including JZP458 in acute lymphoblastic leukemia
- International market penetration for existing specialty products
Key risks
- Competitive and generic pressure on key neuroscience products
- Pipeline execution risk across multiple clinical-stage programs
- Elevated financial risk profile, including debt obligations from prior acquisitions
JAZZ vs Peers
Jazz operates in a competitive specialty pharma and biopharmaceutical landscape alongside companies with distinct therapeutic focuses and business models.
Ionis focuses on RNA-targeted drug discovery, giving it a differentiated platform technology rather than a traditional small-molecule or specialty-drug approach.
Madrigal is concentrated on metabolic liver disease, representing a narrower therapeutic focus compared to Jazz's dual neuroscience and oncology strategy.
Exelixis is primarily an oncology-focused company built around its cabozantinib franchise, with a more concentrated revenue base than Jazz's diversified portfolio.
Frequently Asked Questions
What does Jazz Pharmaceuticals do?
Jazz Pharmaceuticals develops and commercializes specialty pharmaceutical products targeting serious medical conditions. Its two main focus areas are neuroscience — including sleep disorders like narcolepsy — and oncology, covering blood cancers and solid tumors. The company markets several approved products while advancing a clinical pipeline.
Does JAZZ pay dividends?
Jazz Pharmaceuticals does not pay a dividend. The company directs its capital toward pipeline investment, business development, and managing its balance sheet rather than returning cash to shareholders through distributions.
When does JAZZ report earnings?
Jazz Pharmaceuticals follows a standard quarterly earnings cadence for US-listed companies. For specific dates and the most current financial results, check the investor relations section of Jazz Pharmaceuticals' official website.
Is JAZZ a good stock to buy?
UQS Score rates JAZZ as Below Average, driven by Weak readings across Quality, Growth, and Risk pillars. The Valuation pillar is Attractive, which may reflect existing headwinds already priced in. Whether that trade-off suits your portfolio depends on your risk tolerance and investment thesis.
Is JAZZ overvalued?
Based on the UQS Valuation pillar, JAZZ is rated Attractive — meaning the current price appears to reflect the company's challenges rather than a premium. This does not imply a guaranteed return, but suggests the stock is not trading at an elevated multiple relative to its fundamentals.
How does JAZZ compare to its competitors?
Jazz competes with specialty biopharmaceutical companies like Ionis Pharmaceuticals, Madrigal Pharmaceuticals, and Exelixis. Each competitor has a distinct platform or therapeutic focus. Jazz's dual neuroscience and oncology strategy gives it broader diversification, though its overall UQS profile currently lags stronger-rated peers in the sector.
What is JAZZ's market cap bracket?
Jazz Pharmaceuticals is classified as a large-cap company, placing it among the larger publicly traded biopharmaceutical firms by market value.
Who founded Jazz Pharmaceuticals?
Jazz Pharmaceuticals was founded in 2007. Details on the founding team are widely available through public company filings and the company's official history on its investor relations site.
Is JAZZ a long-term quality stock?
As a long-term quality indicator, JAZZ's current UQS profile — with Weak scores across Quality, Growth, and Risk — suggests caution. Long-term quality investing typically favors companies with durable financial strength and consistent growth, areas where Jazz currently faces challenges. Pipeline progress could shift this picture over time.
What is the main competitive advantage of Jazz Pharmaceuticals?
Jazz holds a Neutral Moat rating, reflecting some degree of differentiation through its specialty product portfolio and established presence in narcolepsy treatment. Its oxybate franchise benefits from regulatory complexity and a specialized patient population, though competitive and generic pressures remain ongoing concerns.
What sector does JAZZ belong to?
Jazz Pharmaceuticals operates in the Healthcare sector, specifically within the biopharmaceutical industry. It focuses on specialty therapeutics for neuroscience and oncology indications rather than broad primary-care or generics markets.
Is JAZZ a growth stock or value stock?
Based on its UQS profile, JAZZ presents a mixed picture. The Growth pillar is Weak, suggesting limited near-term expansion momentum, while the Valuation pillar is Attractive — characteristics more aligned with a value-oriented framing, though the underlying risk profile tempers that narrative.
Unlock Full JAZZ Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial quality metrics for JAZZ
- ✓Compare JAZZ against sector peers side by side
- ✓Track pillar changes as new data becomes available
- ✓Screen for higher-rated healthcare stocks in one place
Pro Analysis
JAZZ — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | 43.6 | 37.2 | 43.0 | 37.7 | 27.3 | 79.2 | 0.0 |
| May 14, 2026 | 43.6 | 37.2 | 43.0 | 37.7 | 27.3 | 79.4 | 0.0 |
| May 12, 2026 | 43.6 | 37.2 | 43.0 | 37.7 | 27.3 | 79.6 | +3.3 |
| May 8, 2026 | 40.3 | 5.8 | 43.0 | 37.6 | 37.2 | 100.0 | -1.7 |
| May 7, 2026 | 42.0 | 33.7 | 43.0 | 37.1 | 23.4 | 79.5 | -0.1 |
| May 5, 2026 | 42.1 | 33.7 | 43.0 | 37.1 | 23.4 | 80.0 | 0.0 |
| Apr 27, 2026 | 42.1 | 33.7 | 43.0 | 37.2 | 23.4 | 80.0 | 0.0 |
| Apr 18, 2026 | 42.1 | 33.7 | 43.0 | 37.0 | 23.4 | 80.0 | -3.0 |
| Apr 9, 2026 | 45.1 | 33.7 | 43.0 | 37.0 | 23.4 | 100.0 | 0.0 |
| Apr 2, 2026 | 45.1 | 33.7 | 43.0 | 36.9 | 23.4 | 100.0 | — |
JAZZ — Pillar Breakdown
Quality
— 37.2/100 (25%)Jazz Pharmaceuticals plc has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 37.9/100 (20%)Jazz Pharmaceuticals plc shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 27.3/100 (15%)Jazz Pharmaceuticals plc presents elevated risk with concerns around leverage or financial stability.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 79.2/100 (15%)Jazz Pharmaceuticals plc appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 43/100 (25%)Jazz Pharmaceuticals plc possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for JAZZ.
Score Composition
Financial Data
More Stock Analysis
How is the JAZZ UQS Score Calculated?
The UQS (Unified Quality Score) for Jazz Pharmaceuticals plc is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Jazz Pharmaceuticals plc's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Jazz Pharmaceuticals plc is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.